Cencora, Inc. (BVMF:C1CO34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 306.95B +2.4% |
| Revenue (ttm) | 1.72T +5.1% |
| Net Income | 13.60B +38.3% |
| EPS | 69.74 +39.1% |
| Shares Out | n/a |
| PE Ratio | 22.57 |
| Forward PE | 15.88 |
| Dividend | 4.22 (0.52%) |
| Ex-Dividend Date | Aug 13, 2026 |
| Volume | 3 |
| Open | 818.40 |
| Previous Close | 793.00 |
| Day's Range | 818.40 - 818.40 |
| 52-Week Range | 665.32 - 960.00 |
| Beta | 0.57 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 4, 2026 |
About Cencora
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, ... [Read more]
Financial Performance
In fiscal year 2025, Cencora's revenue was $321.33 billion, an increase of 9.31% compared to the previous year's $293.96 billion. Earnings were $1.55 billion, an increase of 2.99%.
Financial numbers in USD Financial StatementsNews
Cencora Transcript: 2026 Global Healthcare Conference
Leadership highlighted a smooth CFO transition, a focus on specialty pharma and MSO growth, and disciplined capital deployment. MSOs are expected to drive profitability by 2027, with stable customer relationships and no major strategic shifts planned.
Cencora Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Strong specialty pharma growth is expected to continue through 2027, driven by focused investments in oncology and retina, integration of MSO platforms, and robust international performance. Regulatory and customer dynamics are being managed proactively, with capital allocation priorities unchanged.
Cencora Transcript: Wells Fargo 21st Annual Healthcare Conference
Specialty pharmaceuticals and oncology drive strong growth, with international operations rebounding and strategic relationships remaining stable. Minor Walgreens volume shifts were anticipated, and biosimilars, AI, and MSO expansion offer future opportunities. Independent pharmacies remain resilient.
Cencora's Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement to Help Health Systems Build and Scale Programs
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today launched a service to help health systems evaluate, build and scale cell and gene therapy (CGT) programs. Offered through Accelerate Pharmacy Solution...
Cencora Earnings Call Transcript: Q3 2026
Q3 saw strong double-digit adjusted operating income and EPS growth, driven by specialty and MSO performance, the OneOncology acquisition, and robust capital deployment. Fiscal 2026 guidance was raised, with continued momentum expected across U.S. and international segments.
Cencora Earnings release: Q3 2026
Cencora released its Q3 2026 earnings on August 5, 2026, summarizing the period's financial results.
Cencora Slides: Q3 2026
Cencora has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on August 5, 2026.
Cencora Quarterly report: Q3 2026
Cencora has published its Q3 2026 quarterly earnings report on August 5, 2026.
Cencora lifts annual profit view on strong demand for specialty medicines
U.S. drug distributor Cencora raised its annual adjusted profit forecast on Wednesday after quarterly results beat Wall Street expectations, driven by strong demand for specialty medicines.
Cencora Reports Fiscal 2026 Third Quarter Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 third quarter ended June 30, 2026, revenue increased 5.1 percent year-over-year to $84.8 billion. On...
FTC takes closer look at Cencora-Covetrus animal health merger, Bloomberg News reports
The U.S. Federal Trade Commission is taking a closer look at a proposed $3.5 billion acquisition that would combine two of the leading national suppliers of veterinary products, Cencora's MWI Anima...
Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2026 on Wednesday, August 5, 2026, prior to the openi...
Cencora Launches Next-Generation Nucleus® Solution with Multi-Site Pilot Across Specialty Physician Practices
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announced a multi-site pilot of its enhanced Nucleus® inventory management solution, designed to help spec...
Suncrete, Inc. Completes Arkansas Acquisition
Company Enhances Scale and Expands Footprint into New Markets TULSA, Okla., June 15, 2026 /PRNewswire/ -- Suncrete, Inc. (Nasdaq: RMIX) ("Suncrete" or the "Company"), a ready-mix concrete logistics an...
Cencora Announces Samantha Hammock as Chief Human Resources Officer
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that Silvana Battaglia, Executive Vice President and Chief Human Resources Officer (CHRO), has announced she will retire f...
Cencora to Support U.S. Distribution of Kite's CAR T-Cell Therapies
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora today announced an agreement with Kite, a Gilead Company, to support the distribution of Kite's U.S. Food and Drug Administration (FDA)-approved CAR T-cell ...
Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 29, ...
Cencora revises forecast for 2026, approves $2 billion share buyback
U.S. drug distributor Cencora on Thursday raised the lower end of its fiscal 2026 earnings forecast citing recent share repurchases, and also approved a new $2 billion stock buyback plan.
Cencora Announces Updated Fiscal Year 2026 Financial Outlook
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today updated its fiscal year 2026 financial guidance as a result of recent opportunistic share repurchases. Cencora now expects adjusted ...
Cencora Transcript: Bank of America Global Healthcare Conference 2026
Management reaffirmed confidence in full-year and long-term guidance, with EPS expected at $17.65–$17.90 and $1 billion in share repurchases planned. U.S. Healthcare Solutions growth is set to accelerate, M&A integration is progressing well, and AI-driven efficiency initiatives are underway.
Cencora Earnings Call Transcript: Q2 2026
Adjusted EPS grew 7.5% and operating income rose in both core segments, despite revenue headwinds from price reductions, customer losses, and faster biosimilar conversions. Full-year EPS guidance was raised, with strong cash flow and resumed share buybacks supporting long-term growth.
Cencora Earnings release: Q2 2026
Cencora released its Q2 2026 earnings on May 6, 2026, summarizing the period's financial results.
Cencora Slides: Q2 2026
Cencora has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 6, 2026.
Cencora Quarterly report: Q2 2026
Cencora has published its Q2 2026 quarterly earnings report on May 6, 2026.